News
Stay up to date with CellCentric and follow us on Twitter
Key information, updates and news can be found through our tweets
CellCentric’s Finance Director, Thea Stanway at the @BIA_UK’s excellent Women in Biotech meeting, Hinxton, Cambridge. #EmbraceEquity
March is Multiple Myeloma Awareness Month. CellCentric’s oral drug, inobrodib impacts IRF4 and MYC, key drivers of myeloma. Initial clinical data shared at ASH22.
CellCentric’s inobrodib is an oral small molecule drug that inhibits p300/CBP. That impacts key drivers of multiple myeloma, IRF4 and MYC.
CellCentric’s Finance Director, Thea Stanway at the @BIA_UK’s excellent Women in Biotech meeting, Hinxton, Cambridge. #EmbraceEquity
March is Multiple Myeloma Awareness Month. CellCentric’s oral drug, inobrodib impacts IRF4 and MYC, key drivers of myeloma. Initial clinical data shared at ASH22.
CellCentric’s inobrodib is an oral small molecule drug that inhibits p300/CBP. That impacts key drivers of multiple myeloma, IRF4 and MYC.
Multiple key conferences this year, as we share data and meet clinical collaborators. Advancing inobrodib, our pioneering p300/CBP inhibitor.
New oral cancer drug inobrodib is making a difference. Made possible by the combined efforts of patients, physicians, scientists & hospital staff. Thank you. #WorldCancerDay
Many thanks @Labiotech_eu for featuring @CellCentric’s CEO, Will West. Special article on improving cancer care, ahead of #WorldCancerDay2023 https://www.labiotech.eu/in-depth/how-can-cancer-care-be-improved/
CellCentric’s Finance Director, Thea Stanway at the @BIA_UK’s excellent Women in Biotech meeting, Hinxton, Cambridge. #EmbraceEquity
March is Multiple Myeloma Awareness Month. CellCentric’s oral drug, inobrodib impacts IRF4 and MYC, key drivers of myeloma. Initial clinical data shared at ASH22.
CellCentric’s inobrodib is an oral small molecule drug that inhibits p300/CBP. That impacts key drivers of multiple myeloma, IRF4 and MYC.
Multiple key conferences this year, as we share data and meet clinical collaborators. Advancing inobrodib, our pioneering p300/CBP inhibitor.
New oral cancer drug inobrodib is making a difference. Made possible by the combined efforts of patients, physicians, scientists & hospital staff. Thank you. #WorldCancerDay
Many thanks @Labiotech_eu for featuring @CellCentric’s CEO, Will West. Special article on improving cancer care, ahead of #WorldCancerDay2023 https://www.labiotech.eu/in-depth/how-can-cancer-care-be-improved/
CellCentric’s Finance Director, Thea Stanway at the @BIA_UK’s excellent Women in Biotech meeting, Hinxton, Cambridge. #EmbraceEquity
March is Multiple Myeloma Awareness Month. CellCentric’s oral drug, inobrodib impacts IRF4 and MYC, key drivers of myeloma. Initial clinical data shared at ASH22.
CellCentric’s inobrodib is an oral small molecule drug that inhibits p300/CBP. That impacts key drivers of multiple myeloma, IRF4 and MYC.
Multiple key conferences this year, as we share data and meet clinical collaborators. Advancing inobrodib, our pioneering p300/CBP inhibitor.
New oral cancer drug inobrodib is making a difference. Made possible by the combined efforts of patients, physicians, scientists & hospital staff. Thank you. #WorldCancerDay
Many thanks @Labiotech_eu for featuring @CellCentric’s CEO, Will West. Special article on improving cancer care, ahead of #WorldCancerDay2023 https://www.labiotech.eu/in-depth/how-can-cancer-care-be-improved/
Latest press releases
CellCentric presents early haem clinical data at ASH
CellCentric to present haem clinical data at ASH
